DA-0157

• Target :

  ALK|||Cytochromes P450|||EGFR

• Related Pathways :

  Tyrosine Kinase/Adaptors|||Metabolism|||JAK/STAT signaling|||Angiogenesis

• Bioactivity :

  DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC) . It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 ?M), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM) . Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 ?M and demonstrates antitumor activity in mouse models.

• Smiles :

  O=P(C1=CC(=CC=C1NC2=NC(=NC=C2Br)NC=3C=C(C(=CC3OC)N4CCC(N5CCN(C)CC5)CC4)C)C)(C)C

• Molecular Formula :

  C31H43BrN7O2P

• Molecular Weight :

  656.597

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2756978-82-0